[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 184.73.122.162. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
January 1990

Macrophage Migration Inhibition Factor (MIF) in Drug Eruption

Author Affiliations

From the Department of Dermatology (Drs Halevy, Grunwald, and Sandbank), Emergency Room (Dr Buimovice), and Clinical Laboratory (Drs Joshua and Livni), Beilinson Medical Center, Petah Tiqva, and the Sackler School of Medicine, Tel Aviv University, Israel. Drs Halevy and Grunwald are now with the Department of Dermatology, Soroka Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Arch Dermatol. 1990;126(1):48-51. doi:10.1001/archderm.1990.01670250054007
Abstract

• A controlled study was conducted to evaluate the macrophage migration inhibition factor test as a diagnostic aid in 50 patients with drug eruption. Two groups of patients served as controls: group A, 110 patients being treated with drugs without known cutaneous adverse reactions, and group B, 15 patients suffering from dermatologic disorders unrelated to drugs being taken. Positive macrophage migration inhibition factor responses were found toward a variety of drugs in 35 (70%) of the patients with drug eruptions, with no relation to the type of eruption or the duration of drug intake. The percentage of positive macrophage migration inhibition factor responses toward drugs in the patients with drug eruptions was higher than that in the two control groups (4.5% and 6.7%, respectively). The percentage of positive macrophage migration inhibition factor responses recorded for clinically "suspected" drugs was significantly higher than that recorded for the "nonsuspected" drugs.

(Arch Dermatol. 1990;126:48-51)

×